Aurisco Pharmaceutical (SHA:605116) subsidiary Yangzhou Aurisco Pharmaceutical's quality management system passed an inspection by the U.S. Food and Drug Administration, according to a Thursday filing with the Shanghai bourse.
The FDA inspected Yangzhou Aurisco's workshops in Jiangsu, China from June 15 to 19, covering its production facilities and found the workshops to be in compliance with current good manufacturing practice standards, the filing said.
Shares rose 3% during afternoon trading on Thursday.